Daily Endocrinology Research Analysis
Today's top endocrinology research spans neuroendocrine oncology, epidemiologic methods, and social determinants in diabetes. A large prospective cohort clarifies outcomes and prognostic factors in high-grade digestive neuroendocrine neoplasms, a meta-analysis exposes variability in administrative case definitions for PCOS, and a national study links lower education with more adverse clinical profiles at type 2 diabetes diagnosis.
Summary
Today's top endocrinology research spans neuroendocrine oncology, epidemiologic methods, and social determinants in diabetes. A large prospective cohort clarifies outcomes and prognostic factors in high-grade digestive neuroendocrine neoplasms, a meta-analysis exposes variability in administrative case definitions for PCOS, and a national study links lower education with more adverse clinical profiles at type 2 diabetes diagnosis.
Research Themes
- Neuroendocrine oncology outcomes and prognostic stratification
- Validity of administrative data definitions in endocrine epidemiology
- Social determinants of health in early type 2 diabetes care
Selected Articles
1. Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.
In this prospective, population-based cohort of advanced digestive HG-NEN (n=639), NEC had markedly worse outcomes than NET G3 (median OS 7.4 vs 21.8 months; PFS 3.4 vs 7.4 months). Performance status, Ki-67 >55%, ALP, age, and sex predicted OS in NEC, while platinum-based therapy and PS were key in NET G3; sub-effective initial platinum in NET G3 was not compensated by later lines.
Impact: Defines real-world outcomes and prognostic stratification in a large, prospectively accrued HG-NEN cohort and highlights the critical importance of initial therapy quality in NET G3.
Clinical Implications: Use PS, Ki-67, ALP, and age to stratify risk in NEC and consider the adequacy of initial platinum-based therapy for NET G3; avoid sub-effective initial regimens as later lines may not compensate.
Key Findings
- Immediate progression occurred in 41% of NEC vs 24% of NET G3; median PFS 3.4 vs 7.4 months and OS 7.4 vs 21.8 months.
- OS in NEC was associated with PS, Ki-67 >55%, ALP, age, and sex; PFS with colorectal primary and PS.
- In NET G3, platinum-based treatment and PS significantly influenced OS and PFS; sub-effective initial platinum therapy could not be compensated by later lines.
Methodological Strengths
- Prospective, multicenter, population-based cohort with centralized pathology re-evaluation
- Large sample with predefined endpoints (PFS, OS) and subgroup analyses (NEC vs NET G3)
Limitations
- Non-randomized treatment selection limits causal inference regarding regimen efficacy
- Inclusion of elderly and poor PS patients likely contributed to shorter survival and potential selection bias
Future Directions: Prospective trials testing optimized first-line regimens in NET G3, and validation of prognostic models incorporating PS, Ki-67, and ALP across centers.
BACKGROUND: Digestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and classified as neuroendocrine carcinomas (NEC) or neuroendocrine tumours G3 (NET G3), and differ in clinical and molecular characteristics, response to treatment and prognosis. METHODS: Prospective multicenter study registering clinical data on patients with digestive HG-NEN. Treatment outcome in patients with advanced disease was compared after centralized pathological re-evaluation. RESULTS: 427 NEC and 117 NET G3 received palliative chemotherapy. Immediate progression rate was 41% and 24%, progression-free survival (PFS) 3.4 m and 7.4 m, overall survival (OS) 7.4 m and 21.8 m for NEC and NET G3, respectively. Significant factors for OS in NEC were performance status (PS), Ki-67 > 55%, alkaline phosphatase (ALP), age, sex and for PFS colorectal primary and PS. NEC Ki-67 < 55% had similar OS comparing treatment. Significant factors for OS in NET G3 were platinum-based treatment, PS, age and ALP, and for PFS platinum-based treatment. CONCLUSIONS: Survival was shorter than expected in this unique population-based cohort of advanced digestive HG-NEN, likely due to inclusion of elderly and patients with poor PS. Several novel prognostic factors were identified for NEC and NET G3. An initial sub-effective platinum-based treatment for NET G3 could not be compensated by later-line treatment.
2. Validity of administrative health data case definitions for identifying polycystic ovary syndrome: a systematic review and meta-analysis.
This systematic review and meta-analysis identified only four validation studies of administrative PCOS case definitions. ICD code-based definitions showed high pooled PPV (88%) but substantial heterogeneity (I2=100%) and limited sensitivity data, underscoring the need for standardized, validated coding algorithms.
Impact: Provides quantitative evidence on the validity and variability of PCOS case definitions in administrative data, directly informing population-level endocrine epidemiology.
Clinical Implications: Researchers and health systems should not rely on a single ICD code; instead, use validated multi-code algorithms and consider local validation to improve case ascertainment for PCOS.
Key Findings
- Four eligible studies (3 cross-sectional, 1 retrospective cohort) evaluated administrative PCOS definitions.
- All definitions used ICD-9 256.4; three used ICD-10 E28.2; PPV ranged from 30% to 96%.
- Pooled PPV for ICD-based case definitions was 88% (95% CI 82–95%) with high heterogeneity (I2=100%); sensitivity data were sparse (one study 50%).
Methodological Strengths
- Dual independent screening, extraction, and quality assessment with predefined protocol
- Random-effects meta-analysis with heterogeneity assessment; PROSPERO registration
Limitations
- Only four validation studies; precision measures limited and variable across studies
- High heterogeneity (I2=100%) limits generalizability of pooled estimates
Future Directions: Develop and test standardized, multi-variable coding algorithms (e.g., combining ICD, procedure, and prescription data) with external validation across datasets and jurisdictions.
STUDY QUESTION: What is the validity of published administrative health data case definitions of polycystic ovary syndrome (PCOS) compared with reference standards? SUMMARY ANSWER: Due to the limited number of eligible studies, drawing definitive conclusions is challenging; however, this review highlights significant gaps and variability in current PCOS case definitions, underscoring the need for standardized case definitions in future research. WHAT IS KNOWN ALREADY: Administrative health data offer the opportunity to evaluate health outcomes and disease epidemiology at a population-level. Currently, the validity of existing administrative health data case definitions for PCOS is unknown. STUDY DESIGN, SIZE, DURATION: A systematic review of the literature was conducted on full-text English-language articles up to July 2023, using the MEDLINE and EMBASE databases. PARTICIPANTS/MATERIALS, SETTING, METHODS: Two reviewers independently screened titles, abstracts and full texts, extracted data, assessed study quality and graded validity. A random effects meta-analysis was conducted to pool reported validity measures and heterogeneity was examined. MAIN RESULTS AND THE ROLE OF CHANCE: The review included four eligible articles consisting of three cross-sectional studies and one retrospective cohort study. Two studies defined PCOS using the Rotterdam Criteria, one study used self-report, and one used a clinical gold standard. All case definitions included the International Classification of Diseases (ICD)-9 code 256.4 for 'polycystic ovaries' and three studies used E28.2 for 'polycystic ovarian syndrome'. Three studies reported positive predictive value (PPV), which ranged from 30 to 96%. One study reported both PPV (96%) and sensitivity (50%) for one case definition. The pooled PPV estimate for the ICD code-based case definitions was 88% (95% confidence interval 82-95%; I2 = 100%). One study reported fair agreement (percent agreement= 90.3, κ = 0.27, percent agreement bias adjusted κ = 0.81). Overall, the risk of bias of the included studies was low. LIMITATIONS, REASONS FOR CAUTION: There were limited number of validations and precision indices of validations. WIDER IMPLICATIONS OF THE FINDINGS: Further validation of these case definitions in other administrative health datasets, and development of novel coding algorithms is required to inform future population-based studies in PCOS. STUDY FUNDING/COMPETING INTEREST(S): No external funding was used and there are no disclosures. REGISTRATION NUMBER: PROSPERO CRD42023385617.
3. Educational inequalities in clinical presentation and pharmacological treatment of early type 2 diabetes: A Danish prevalence study.
Among 10,020 newly diagnosed T2D patients, lower education was linked to higher obesity, smoking, sedentary behavior, and more cardiovascular and microvascular complications at diagnosis, along with higher triglycerides and worse kidney function. Use of cardioprotective and newer organ-protective diabetes medications was similar or higher in those with lower education.
Impact: Highlights concrete, quantifiable social gradients at T2D diagnosis that persist despite access to modern therapies, informing equitable risk stratification and targeted interventions.
Clinical Implications: At diagnosis, incorporate social determinants (education) into risk assessment, intensify lifestyle support and complication screening for lower-education patients, and ensure sustained access to organ-protective therapies.
Key Findings
- Lower vs higher education: obesity 58% vs 49% (aPR 1.20, 95% CI 1.14–1.28); current smoking 22% vs 15% (aPR 1.53, 1.32–1.76); sedentary 21% vs 15% (aPR 1.36, 1.20–1.55).
- Cardiovascular complications 23% vs 17% (PR 1.30, 1.16–1.46) and microvascular complications 16% vs 13% (aPR 1.18, 1.02–1.35) were more frequent with lower education.
- Lower education associated with higher triglycerides, greater insulin resistance, and poorer kidney function; HbA1c, BP, and LDL cholesterol were similar across groups.
Methodological Strengths
- Large national cohort of newly diagnosed T2D with detailed phenotyping
- Adjusted prevalence ratios accounting for age and sex across multiple clinical domains
Limitations
- Cross-sectional analysis at diagnosis limits causal inference
- Residual confounding by unmeasured socioeconomic and healthcare access factors possible
Future Directions: Integrate socioeconomic variables into predictive care pathways and test tailored lifestyle and complication-screening interventions in pragmatic trials targeting lower-education groups.
AIMS: To examine how educational attainment impacts clinical presentation and pharmacological treatment at type 2 diabetes (T2D) diagnosis. METHODS: Cross-sectional analysis of 10,020 individuals with recently diagnosed T2D enrolled in the Danish prospective DD2 cohort. Sex- and age-adjusted prevalence ratios (aPRs) for detailed clinical characteristics and pharmacotherapy were computed. RESULTS: In total, 31 % had low, 50 % had moderate, and 19 % had high educational level. Individuals with low rather than high educational level were more often obese (58 % vs 49 %, aPR 1.20 [95 % CI 1.14-1.28]); had less healthy lifestyles (current smokers: 22 % vs 15 %, aPR 1.53 [1.32-1.76]); sedentary activity level: 21 % vs 15 %, aPR 1.36 [1.20-1.55]); and had more often cardiovascular (23 % vs. 17 %, PR 1.30 [1.16-1.46]) and microvascular complications (16 % vs 13 %, aPR 1.18 [1.02-1.35]). Low education associated with higher triglycerides, more insulin resistance, and poorer kidney function, whereas HbA1c, blood pressure, and LDL cholesterol were identical. The use of medications with cardiovascular benefits and newer organ-protective diabetes medications was similar to, or higher than, that in individuals with high education. CONCLUSIONS: Awareness of the impact of social and educational determinants on T2D presentation at diagnosis is essential to improve treatment and prognosis.